▲May 14-15Shanghai BiopharmaceuticalsInnovators SummitScan to register

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to leave comments to point them out. This article is solely for the introduction of medical and health-related drugs.Non-therapeutic program recommendations (if applicable); This article does not constitute any investment advice.。

PharmaCircleMonitoring Shows: Artificial Intelligence GiantAnthropicIn$400 millionin an all-stock transaction, acquired the nascent AI biotech startupCoefficient Bio. This transaction was completed on April 3, 2026.Coefficient BioAll team members will be merged intoAnthropicByEric Kauderer-AbramsLeader of the Healthcare and Life Sciences Department.

Coefficient BioFounded only 8 months ago, with less than 10 employees, the core team almost all comes from Roche's...GenentechComputational Drug Discovery DepartmentPrescient DesignThe company focuses on developing AI models to automate complex laboratory R&D processes, covering areas such as drug development planning, clinical regulatory strategy management, and candidate drug discovery.

Founder Background

Coefficient BioThe core founding team consists ofNathan C. Frey, PhD、Samuel Stanton, PhDAndAris TheologisComposition.Nathan C. FreyAs the Chief Technology Officer (CTO), holding a Ph.D. in Materials Science and Engineering from the University of Pennsylvania, formerlyGenentech Prescient DesignTeam Leader and Chief Machine Learning Scientist, leading the development of biological foundation models and AI strategies for large molecule drug discovery, guiding an interdisciplinary team in developing machine learning-driven biomolecular design methods, and establishing...NVIDIAInBioNeMoKey partnerships.

Samuel StantonAs the Chief Machine Learning Scientist, holding a Ph.D. in Data Science from New York University, also hailing fromPrescient Design, isGenentechCore developer of the bio deep learning library, leading the modular architecture for drug discoveryCortexMolecular Representation Open Source StandardBeignetDesign.

Aris TheologisServing as Chief Executive Officer (CEO), with a background in biochemistry and biophysics from Stanford University and an MBA degree from Harvard Business School, formerlyEvozyneChief Business Officer,Paragon BiosciencesVice President, with extensive experience in biopharmaceutical commercial strategy and AI collaboration expansion.

Investor Background

Coefficient BioThe sole institutional investor isDimension, a venture capital fund founded in New York in 2023, focused on science and computing, by the formerLux CapitalandObvious VenturesPartnerAdam Goulburn、Zavain DarFounded. The fund focuses on cutting-edge technology tracks such as AI-driven life sciences and computational biology, with an investment strategy of early heavy investment and deep empowerment.

References:

PharmaCircle Data;

Moxie Pharma pharma.bcpmdata.com (formerly known as Yaoke Rongyun Data);

http://www.marketscreener.com；

https://www.businesswire.com；

www1.hkexnews.hk/；

https://www.healthcare.digital/single-post/biological-intelligence-strategic-rationale-for-anthropic-s-400-million-acquisition-of-coefficient；

Etc.